All In Biotech

Drug Trial Radar · NCT02409290

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

588

Actual

Start

Mar 2016

Primary completion

May 13, 2022

Study completion May 2, 2023

Sponsor

Lead sponsor
IUATLD, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Council; Institute of Tropical Medicine, Belgium; Liverpool School of Tropical Medicine; Rede TB
First posted
Apr 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tuberculosis (TB) is a common, infectious, bacterial disease that is spread when an infected person transmits their saliva through the air by coughing or sneezing. Despite the availability and effectiveness of affordable six-month treatments for tuberculosis (TB), the worldwide control of this disease is currently being impacted by the emergence of multidrug resistant TB (MDR-TB). MDR-TB refers to TB that is resistant to at least isoniazid and rifampicin. These are the two most powerful first-line drugs used to treat pulmonary TB. MDR-TB usually develops while a person is taking TB treatment due to either inappropriate treatment or failure of patients to comply with their treatment. This strain of drug-resistant bacteria can also be spread to other people through the air. With the incident rate of MDR-TB on the rise, there is a need to investigate optimal treatment regimens using effective drugs.

Conditions

  • MDR-TB

Interventions

  • Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)Drug

    Drug: Locally-used WHO-approved MDR-TB regimen

  • MoxifloxacinDrug

    Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone

  • ClofazimineDrug

    Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.

  • EthambutolDrug

    Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.

  • PyrazinamideDrug

    Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.

  • IsoniazidDrug

    Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.

  • ProthionamideDrug

    Prothionamide has a bacteriostatic action.

  • KanamycinDrug

    Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.

  • LevofloxacinDrug

    Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.

  • BedaquilineDrug

    Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76)Time frame: 76 weeks

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • Armauer Hanssen Research Institute

    Addis Ababa, Ethiopia

  • St. Peter's Tuberculosis Specializes Hospital

    Addis Ababa, Ethiopia

  • JSC National Center for Tuberculosis and Lung Diseases

    Tbilisi, Georgia

  • BJ Medical College Civil Hospital

    Ahmedabad, India

  • The National Institute for Research in Tuberculosis

    Chennai, India

  • Rajan Babu Institute for Pulmonary Medicine and Tuberculosis

    New Delhi, India

  • Institute of Phthisiopneumology 'Chiril Draganiuc'

    Chisinau, Moldova

  • National Centre for Communicable Diseases

    Ulaanbaatar, Mongolia

  • King Dinizulu Hospital

    Durban, South Africa

  • Helen Joseph Hospital

    Johannesburg, South Africa

  • Doris Goodwin Hospital

    Pietermaritzburg, South Africa

  • Empilweni TB Hospital

    Port Elizabeth, South Africa

  • Makerere University (Mulago Referral Hospital)

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.